Print

Purpose

The main purpose of this study is to compare 3 different forms of LY4065967 - a tablet and 2 types of capsule - to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 7 weeks and will include 3 stays in the Clinical Research Unit (CRU). Each stay will last 3 nights.

Condition

Eligibility

Eligible Ages
Between 18 Years and 55 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests. - Have clinical laboratory test results within normal reference range for the population or investigative site. - Have an electrocardiogram (ECG) at screening considered to be within acceptable limits by the investigator. - Have a body mass index within the range 18.0 to 35.0 kilograms per square meter (kg/m²) (inclusive). - Individuals assigned male at birth (AMAB) or assigned female at birth (AFAB) may participate in this trial. - Have venous access sufficient to allow for blood sampling.

Exclusion Criteria

  • Have a history of or current clinically significant medical conditions, including cardiovascular disease, electrolyte abnormalities, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disorders that, in the judgment of the investigator, could predispose to arrhythmia, pose a risk with study participation, significantly alter the absorption, metabolism, or elimination of the study drug, or interfere with the interpretation of study data. - Have systolic blood pressure of 140 millimeters of mercury (mmHg) or greater and diastolic blood pressure of 90 mmHg or greater at screening. - Have a history of clinically significant known allergies to LY4065967, related compounds, or any components of the formulation, or history of significant atopy. - Have a history of alcohol, opioids, stimulants or hallucinogens use disorder within 2 years prior to screening or a current use disorder by Diagnostic and Statistical Manual of Mental Disorders (APA 2013).

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover Assignment
Primary Purpose
Basic Science
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
LY4065967 (Reference) 		Administered orally as a capsule in one of three treatment periods.
  • Drug: LY4065967 Capsule
    Administered orally
Experimental
LY4065967 (Test 1) 		Administered orally as a tablet in one of three treatment periods.
  • Drug: LY4065967 Tablet
    Administered orally
Experimental
LY4065967 (Test 2) 		Administered orally as a formulated capsule in one of three treatment periods.
  • Drug: LY4065967 Formulated Capsule
    Administered orally

Recruiting Locations

Fortrea Clinical Research Unit
Daytona Beach, Florida 32117
Contact:
386-366-6400

Fortrea Clinical Research Unit
Dallas, Texas 75247
Contact:
214-647-9375

More Details

Status
Recruiting
Sponsor
Eli Lilly and Company

Study Contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559
LillyTrials@Lilly.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.